HK inno.N Corporation will be responsible for the manufacture and supply of Tegoprazan, while Dr. Reddy's will handle local clinical development, registration, marketing and sales
Adds five years of market exclusivity on approval
A preview on Q3FY22 by Nirmal Bang Securities on select Indian pharma companies
Idiopathic hypersomnia is a life-long condition, and the approval of Xywav will be instrumental in providing treatment for symptoms such as excessive sleepiness and difficulty waking, and in effectively managing this debilitating disorder
The DREAM-ND Phase III trial has now enrolled 588 CKD patients not-on-dialysis.
Subscribe To Our Newsletter & Stay Updated
